Clinical trials: Recurrent Cholangiocarcinoma
Cancer
Gene Therapy in Treating Patients With Cancer
RATIONALE: Inserting a gene that has been created in the laboratory into a person's white blood cells may make the body build an immune response to kill cancer cells.
- Trial name
- NCT00004178
- Testing
- therapeutic autologous lymphocytes
- Where
- United States
- Sponsor
- Roger Williams Medical Center
Cholangiocarcinoma, Intrahepatic, Recurrence Cholangiocarcinoma
Surgery for Recurrent Intrahepatic Cholangiocarcinoma
The investigators retrospectively reviewed the participants suffering from recurrent intrahepatic cholangiocarcinoma after curative resection and aimed to explore the predictive factors for recurrence and clarify the potential…
- Conditions
- Cholangiocarcinoma, Intrahepatic, Recurrence Cholangiocarcinoma, Re-hepatectomy
- Trial name
- NCT04072250
- Testing
- hepatectomy
- Where
- Taiwan
- Volunteers
- 216 people
- Sponsor
- Chang Gung Memorial Hospital
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating patients with liver…
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00003296
- Testing
- filgrastim, pegylated liposomal doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Brown University
Intrahepatic Cholangiocarcinoma
PD-1 Antibody (SHR-1210) Plus Capecitabine in Patients with Intrahepatic Cholangiocarcinoma After Surgery
SHR-1210 is a humanized anti-PD-1 Immunoglobulin G4 (IgG4) monoclonal antibody. This is an open- label,single center,non-randomized ,single arm exploratory study .
- Trial name
- NCT04295317
- Testing
- PD-1 blocking antibody SHR-1210, Capecitabine
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Shanghai Zhongshan Hospital
Pancreatic Adenocarcinoma, Pancreatic Cysts
Robotic Versus Open Pancreaticoduodenectomy for Pancreatic and Periampullary Tumors
This multicenter randomized trial aims to primarily assess and compare the functional recovery of patients who undergo open versus robotic pancreaticoduodenectomy for benign and malignant lesions of the head of the pancreas.
- Conditions
- Pancreatic Adenocarcinoma, Pancreatic Cysts, Pancreatic Endocrine Tumors, Chronic Pancreatitis
- Trial name
- PORTAL (NCT04400357)
- Testing
- Robotic pancreaticoduodenectomy, Open pancreaticoduodenectomy
- Where
- China
- Volunteers
- 268 people
- Sponsor
- Ruijin Hospital
Biliary Tract Neoplasms, Recurrence
A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
The purpose of this study is to assess the difference of safety and efficacy about Capecitabine and S-1 for treatment of patients with low-risk of recurrence after BTC surgery.
- Conditions
- Biliary Tract Neoplasms, Recurrence, Cholangiocarcinoma, Gall Bladder Cancer
- Trial name
- NCT04856761
- Testing
- S-1, Capecitabine
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Fudan University
Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of vaccine therapy with or without sargramostim in treating patients who have advanced or metastatic cancer. Vaccines may make the body build an immune response to kill tumor cells.
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder, Adenocarcinoma of the Pancreas, Adenocarcinoma of the Rectum
- Trial name
- NCT00028496
- Testing
- recombinant fowlpox-CEA(6D)/TRICOM vaccine, sargramostim, recombinant fowlpox GM-CSF vaccine adjuvant
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trametinib or combination chemotherapy works in treating patients with refractory or advanced biliary or gallbladder cancer or that cannot be removed by surgery.
- Conditions
- Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma
- Trial name
- S1310 (NCT02042443)
- Testing
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis
- Where
- 295 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Cancer, Ampullary Cancer
Recurrence After Whipple's (RAW) Study
Pancreatic head malignancies are aggressive cancers that are often inoperable when they are diagnosed. In the ~20% of patients who are diagnosed when the disease is still operable, surgery is the only treatment that can provide a…
- Conditions
- Pancreatic Cancer, Ampullary Cancer, Bile Duct Cancer, Cholangiocarcinoma, Extrahepatic
- Trial name
- NCT04596865
- Testing
- Pancreaticoduodenectomy
- Where
- 29 sites in Australia, Austria and 6 more
- Volunteers
- 1,484 people
- Sponsor
- University Hospital Plymouth NHS Trust
Peripheral T Cell Lymphoma, Diffuse Large B Cell Lymphoma
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
This study evaluates the efficacy, as measured by the objective response rate, of STI-3031, an anti-PD-L1 antibody, in previously treated patients with selected advanced lymphomas or biliary tract cancer.
- Conditions
- Peripheral T Cell Lymphoma, Diffuse Large B Cell Lymphoma, Biliary Tract Cancer, Extranodal NK T Cell Lymphoma, Nasal
- Trial name
- NCT03999658
- Testing
- STI-3031
- Sponsor
- Sorrento Therapeutics, Inc.
Durvalumab, Intrahepatic Cholangiocarcinoma
Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk
This study is a randomized controlled study to evaluate the efficacy and safety of Durvalumab combined with GemCis for neoadjuvant treatment of high recurrence risk ICC
- Conditions
- Durvalumab, Intrahepatic Cholangiocarcinoma, Gemcis
- Trial name
- NCT05672537
- Testing
- Durvalumab, Surgery, Gemcitabine
- Where
- China
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Combination Chemotherapy in Treating Patients With Unresectable or Metastatic Biliary Tract or Gallbladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00009893
- Testing
- fluorouracil, gemcitabine hydrochloride, leucovorin calcium
- Where
- 19 sites in United States
- Volunteers
- 42 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery
This phase II trial is studying how well lapatinib works in treating patients with locally advanced or metastatic biliary tract or liver cancer that cannot be removed by surgery.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00101036
- Testing
- lapatinib ditosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural Effusions
RATIONALE: Using BG00001 to insert the gene for interferon-beta into a person's pleural cavity may improve the body's ability to fight cancer.
- Trial name
- NCT00066404
- Testing
- recombinant adenovirus-hIFN-beta
- Where
- United States
- Sponsor
- Abramson Cancer Center at Penn Medicine
Neoplasms
Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors
The key purpose of the main part of the study is to assess efficacy and safety of anetumab ravtansine as monotherapy or combination therapy for mesothelin expressing advanced solid tumors.
- Trial name
- ARCS-Multi (NCT03102320)
- Testing
- Cisplatin, Gemcitabine, Anetumab ravtansine (BAY94-9343)
- Where
- 72 sites in United States, Australia and 10 more
- Volunteers
- 173 people
- Sponsor
- Bayer
Intrahepatic Cholangiocarcinoma
TACE Plus Tegafur Versus TACE for Intrahepatic Cholangiocarcinoma After Curative Resection
The aim of this study is to compare the outcomes of Transarterial Chemoembolization (TACE) plus Tegafur with TACE alone in patients with intrahepatic cholangiocarcinoma after curative resection
- Trial name
- NCT02588755
- Testing
- TACE+Tegafur, TACE
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Cancer Pain, Visceral Pain
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL).
- Conditions
- Cancer Pain, Visceral Pain, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract
- Trial name
- NCT04907643
- Testing
- PICO G2 4k
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Cedars-Sinai Medical Center
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Photodynamic Therapy in Treating Patients With Cancer of the Bile Duct, Gallbladder, or Pancreas
RATIONALE: Photodynamic therapy uses light and drugs that make cancer cells more sensitive to light to kill tumor cells. This may be effective treatment for cancer of the bile duct, gallbladder, or pancreas.
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Pancreatic Cancer
- Trial name
- NCT00003923
- Testing
- porfimer sodium
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
HER2-positive Breast Cancer, HER2 Gene Mutation
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Open-label, Phase I-II, first-in-human (FIH) study for A166 monotherapy in HER2-expressing or amplified patients who progressed on or did not respond to available standard therapies.
- Conditions
- HER2-positive Breast Cancer, HER2 Gene Mutation, HER-2 Gene Amplification, HER2 Positive Gastric Cancer
- Trial name
- NCT03602079
- Testing
- A166
- Where
- 10 sites in United States
- Volunteers
- 49 people
- Sponsor
- Klus Pharma Inc.
Gastric Cancer, Colorectal Cancer
A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer
This study is to define the safety profile and to determine the Maximal tolerated dose regimen and preliminary efficacy of AbGn-107 administered every 14 days (Q2W regimen) or 28 days (Q4W regimen) in patients with…
- Conditions
- Gastric Cancer, Colorectal Cancer, Pancreatic Cancer, Biliary Cancer
- Trial name
- NCT02908451
- Testing
- AbGn-107
- Where
- 9 sites in United States, Taiwan
- Volunteers
- 39 people
- Sponsor
- AbGenomics B.V Taiwan Branch